| Angela Fisher, | |
|
353 Fairmont Blvd, Rapid City, SD 57701-7375 | |
| (605) 755-8333 | |
| Not Available |
| Full Name | Angela Fisher |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Neonatal |
| Location | 353 Fairmont Blvd, Rapid City, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265818462 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Angela Fisher, 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Angela Fisher, 353 Fairmont Blvd, Rapid City, SD 57701-7375 Ph: (605) 755-8333 |
News Archive
Amyloid precursor protein (APP), a key protein implicated in the development Alzheimer's disease, may play an important role in eye and muscle health. In a new report published in the June 2015 issue of The FASEB Journal, scientists have discovered that when proteins that bind to the APP, called FE65 and FE65L1, are deleted, they cause cataracts and muscle weakness in mice.
Genetics can be used to predict a patient's response to antipsychotic drug treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research. The findings were published online today in the American Journal of Psychiatry.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2010. For the second quarter, AMAG reported total revenue of $18.8 million, including $16.0 million of Feraheme® (ferumoxytol) Injection for intravenous (IV) use net product revenues.
At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).
› Verified 4 days ago
Maria Sargent, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-755-1000 | |
Kayla Sayer, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 640 Flormann St, Rapid City, SD 57701 Phone: 605-755-3300 | |
Jennifer Ann Erdman, CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 636 Saint Anne St, Rapid City, SD 57701 Phone: 605-348-8000 Fax: 605-348-4315 | |
Natasha Gray, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2805 5th St, Rapid City, SD 57701 Phone: 605-755-5700 | |
Morgan Folchert, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1760 Centre St Ste 2, Rapid City, SD 57703 Phone: 308-249-2912 | |
Paulette A Kirby, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 811 Columbus St, Rapid City, SD 57701 Phone: 605-343-3007 | |
Rebecca Bierle, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4150 5th St, Rapid City, SD 57701 Phone: 605-755-4300 |